infliximab-axxq
E851093
Infliximab-axxq is a monoclonal antibody biosimilar to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
All labels observed (2)
| Label | Occurrences |
|---|---|
| infliximab | 1 |
| infliximab-axxq canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T10214689 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: infliximab-axxq Context triple: [Avsola, hasInternationalNonproprietaryName, infliximab-axxq]
-
A.
infliximab-qbtx
Infliximab-qbtx is a monoclonal antibody biosimilar to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
B.
infliximab-dyyb
Infliximab-dyyb is a monoclonal antibody biosimilar to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
C.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
D.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
E.
Humira
Humira is a widely used biologic medication (adalimumab) that treats various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease by inhibiting tumor necrosis factor (TNF).
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: infliximab-axxq Target entity description: Infliximab-axxq is a monoclonal antibody biosimilar to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
A.
infliximab-qbtx
Infliximab-qbtx is a monoclonal antibody biosimilar to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
B.
infliximab-dyyb
Infliximab-dyyb is a monoclonal antibody biosimilar to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
C.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
D.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
E.
Humira
Humira is a widely used biologic medication (adalimumab) that treats various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease by inhibiting tumor necrosis factor (TNF).
- F. None of above. chosen
Statements (24)
| Predicate | Object |
|---|---|
| instanceOf |
biologic medicinal product
ⓘ
biosimilar medicinal product ⓘ monoclonal antibody ⓘ |
| belongsToGroup |
TNF inhibitors
ⓘ
biologic disease-modifying antirheumatic drugs ⓘ |
| biosimilarTo |
infliximab
ⓘ
linked to:
infliximab-axxq
|
| hasBiosimilarRelationship |
highly similar to reference infliximab
ⓘ
no clinically meaningful differences in safety and effectiveness compared with reference infliximab ⓘ |
| hasDrugClass | tumor necrosis factor alpha inhibitor ⓘ |
| hasMolecularType | chimeric monoclonal antibody ⓘ |
| hasTarget | tumor necrosis factor alpha ⓘ |
| indicatedFor |
moderate to severe Crohn’s disease
ⓘ
moderate to severe rheumatoid arthritis ⓘ moderate to severe ulcerative colitis ⓘ |
| isIntendedUse | chronic systemic therapy ⓘ |
| mechanismOfAction |
binds to soluble and transmembrane TNF-alpha
ⓘ
neutralizes biological activity of TNF-alpha ⓘ |
| routeOfAdministration | intravenous ⓘ |
| therapeuticEffect |
reduces inflammation
ⓘ
suppresses immune response ⓘ |
| usedFor |
Crohn’s disease
ⓘ
autoimmune inflammatory diseases ⓘ rheumatoid arthritis ⓘ ulcerative colitis ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: infliximab-axxq Description of subject: Infliximab-axxq is a monoclonal antibody biosimilar to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: infliximab-axxq